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Abstract
We previously produced a recombinant version of the human anti-RhD antibody Fog-1 in the rat myeloma cell line, YB2/0.
When human, autologous RhD-positive red blood cells (RBC) were sensitised with this IgG1 antibody and re-injected, they
were cleared much more rapidly from the circulation than had been seen earlier with the original human-mouse
heterohybridoma-produced Fog-1. Since the IgG have the same amino acid sequence, this disparity is likely to be due to
alternative glycosylation that results from the rat and mouse cell lines. By comparing the in vitro properties of YB2/0-
produced Fog-1 IgG1 and the same antibody produced in the mouse myeloma cell line NS0, we now have a unique
opportunity to pinpoint the cause of the difference in ability to clear RBC in vivo. Using transfected cell lines that express
single human FccR, we showed that IgG1 made in YB2/0 and NS0 cell lines bound equally well to receptors of the FccRI and
FccRII classes but that the YB2/0 antibody was superior in FccRIII binding. When measuring complexed IgG binding, the
difference was 45-fold for FccRIIIa 158F, 20-fold for FccRIIIa 158V and approximately 40-fold for FccRIIIb. The dissimilarity
was greater at 100-fold in monomeric IgG binding assays with FccRIIIa. When used to sensitise RBC, the YB2/0 IgG1
generated 100-fold greater human NK cell antibody-dependent cell-mediated cytotoxicity and had a 103-fold advantage
over the NS0 antibody in activating NK cells, as detected by CD54 levels. In assays of monocyte activation and macrophage
adherence/phagocytosis, where FccRI plays major roles, RBC sensitised with the two antibodies produced much more
similar results. Thus, the alternative glycosylation profiles of the Fog-1 antibodies affect only FccRIII binding and FccRIII-
mediated functions. Relating this to the in vivo studies confirms the importance of FccRIII in RBC clearance.
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Introduction
For 40 years, human polyclonal anti-RhD antibodies have been
used successfully in the prophylactic treatment of haemolytic
disease of the foetus and newborn to prevent the immunisation of
RhD-negative women by RhD-positive foetal RBC. The precise
mechanisms by which the polyclonal anti-RhD IgG suppress
immunisation against the RhD antigen are not fully understood
but involve rapid, non-inflammatory, FccR-mediated sequestra-
tion of the RhD-positive cells [1,2]. There is evidence that
FccRIIIa plays the major role in this clearance of sensitised RBC.
Most notably, RBC clearance was slower following administration
of an anti-FccRIII monoclonal antibody to chimpanzees and to a
patient [3,4]. Due to the problems implicit in the use of antibodies
from hyperimmune plasma, there has been a drive to identify
effective monoclonal anti-RhD antibodies with which to replace
polyclonal anti-RhD. As a result, monoclonal anti-RhD antibodies
form perhaps the largest group of different antibodies against the
same antigen that have been tested in humans. It appears that the
most efficient antibodies for RBC clearance are those that give
good antibody-dependent cell-mediated cytotoxicity (ADCC) with
NK cells [5,6]. This does not necessarily imply that NK cells are
involved in RBC clearance but that this assay is a good measure of
ability to interact with FccRIIIa. Phagocytosis by splenic
macrophages is held to be the mechanism of IgG-sensitised
RBC destruction but to achieve this by engagement of the high
affinity IgG receptor, FccRI, would require displacement of serum
IgG, which occupies its binding site under physiological condi-
tions. Strong binding of RBC-bound antibody to the intermediate
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affinity FccRIIIa may allow rapid association of RBC and
macrophages. This could both activate the macrophages directly
and promote interactions via FccRI molecules upon dissociation of
non-specific IgG from their binding sites.
One of our interests lies in the development of mutated human
IgG constant regions with different combinations of properties that
can be tailored for therapeutic use. Combining these constant
regions with the variable regions of the human anti-RhD IgG1
antibody Fog-1 [7] allowed measurement of their activity in
various in vitro assays and offered the potential to study their effect
on the intravascular survival of RBC in humans. Accordingly,
aliquots of autologous RBC were labeled with different radionu-
clides and coated with either Fog-1 IgG1 antibody or a mutated
version with reduced effector function (Fog-1 G1Dnab) before
reinjection [8]. As anticipated, clearance of cells coated with Fog-1
G1Dnab from the circulation was significantly slower than the
clearance of wild-type IgG1-coated cells. IgG1-mediated clearance
was complete and irreversible, with accumulation in the spleen
and liver and the appearance of radiolabel in plasma. Notably, the
clearance mediated by our recombinant Fog-1 IgG1 was much
more rapid than seen in a previous study that used the original
Fog-1 antibody at comparable coating levels [9]. Monoclonal anti-
RhD IgG do range widely in their ability to mediate RBC
clearance and, whilst some of this variation results from the
properties of the different variable regions and the choice of IgG1
or IgG3 constant regions, the cell line used for expression of the
IgG appears to be crucial [5]. It is therefore relevant that the
original Fog-1 was obtained from human-mouse heterohybridoma
cells following fusion of Epstein-Barr virus-transformed B
lymphocytes with the mouse myeloma line X63-Ag8.653 [10]
whereas transfected YB2/0 rat myeloma cells were used for the
production of both recombinant Fog-1 G1 and G1Dnab. The cell
line influences the effector properties of an antibody sample by
being responsible for its glycosylation profile.
IgG heavy chain carbohydrate moieties are linked to N297 of
each chain, fill the space between the two CH2 domains and play
roles in the stability and interactions of the Fc (reviewed [11]).
Each oligosaccharide is of the complex biantennary type and
consists of a basic heptasaccharide structure that can be enlarged
by the presence of fucose on the primary N-acetylglucosamine
(GlcNAc) residue, galactose (6sialic acid) on one or both of the
terminal GlcNAc and a bisecting GlcNAc residue. Absence of
carbohydrate results in a decrease in binding to all classes of Fc
receptor whilst changing the oligosaccharide structure can modify
binding. Serial truncation of Fc carbohydrate structures results in
the movement of CH2 domains towards each other and
conformational changes in the FccR interface region that make
receptor binding less favourable [12].
Apart from the Fog-1 studies, the only clinical investigation of
anti-RhD antibodies that were produced from alternative cell lines
involved a BRAD-5 and BRAD-3 mixture [13]. In contrast to the
dissimilar RBC clearance rates of the two Fog-1 IgG1, comparable
rates were mediated by the BRAD antibodies from EBV-
immortalised human cell lines and CHO cells. We wished to
understand the difference in potency between the Fog-1 IgG1from
YB2/0 and the original Fog-1 from human-mouse heterohybri-
doma cells by comparing the properties of IgG carrying
glycosylation that is typical of the products of rat or mouse cell
lines. We chose to compare the YB2/0-produced Fog-1 IgG1 with
the same antibody produced in the mouse myeloma cell line NS0
since this is a line commonly used for therapeutic antibody
production.
Comparison has previously been made between the activities of
antibodies produced in YB2/0, NS0 and CHO cells [14]. When
produced in YB2/0 cells, the humanised IgG1 antibody
CAMPATH-1H was approximately 30-fold more efficient in
ADCC assays than the same antibody made in either NS0 or
CHO cells whilst the antibodies were equally active in monocyte
killing assays. Oligosaccharide analysis showed that YB2/0-
produced antibody contained less fucose (6–7% against 90% for
CHO) and more bisecting GlcNAc residues than IgG made in
CHO or NS0. These two properties are related since fucosylation
prevents enzymatic addition of bisecting GlcNAc. The NS0- and
CHO-derived antibodies contained carbohydrate of a similar
structure but the NS0 IgG1 was significantly underglycosylated.
Fractionation of the IgG showed that it was the lack of fucose,
rather than the presence of bisecting GlcNAc, that led to YB2/0-
produced IgG1 being more efficient at ADCC [15]. Furthermore,
when YB2/0 cells were caused to over-express FUT8 mRNA to
supplement their low levels a1,6-fucosyltransferase, this led to
IgG1 with 81% fucosylation and 100-fold lower ADCC.
Since most of the literature that examines the effects of cell-
specific glycosylation involves IgG produced in CHO cells, there
has been no systematic comparison of YB2/0- and NS0-produced
IgG. Although NS0 and CHO cell lines yield IgG with similar
distributions of glycan structures, the presence of aglycosyl IgG in
NS0 samples potentially reduces binding to all classes of FccR.
Here we evaluate the relative levels of binding of YB2/0- and
NS0-produced Fog-1 IgG1 to a series of transfected cell lines that
separately bear each type of human FccR. We also test the
antibodies’ performance in ADCC, NK cell and monocyte
activation and macrophage adherence and phagocytosis assays.
So that the impact of altering the glycosylation profile of the
antibody can be compared to the change in binding achieved
through amino acid mutation, in some assays we include the Fog-1
IgG1 mutant with reduced activity, Fog-1 G1Dnab, made in YB2/
0 or NS0 cells. As well as definitively assessing the relative levels of
interaction of YB2/0- and NS0-produced IgG1 with the different
FccR, this work reinforces what is known about the mechanism of
IgG-sensitised RBC clearance.
Materials and Methods
Antibody production and characterisation
The production of recombinant IgG1 and mutant G1Dab forms
of Fog-1 in YB2/0 rat myeloma cells [16] and their subsequent
characterisation has been described [17–19]. Fog-1 G1Dnab was
produced by removing the G1m(1,17) allotypic residues from
G1Dab, without effect on its properties [8]. Both wildtype and
mutant Fog-1 antibodies were similarly produced from NS0 mouse
myeloma cells [20]. The antibodies are denoted as Fog-1 G1 and
Fog-1 G1Dnab followed by (YB2/0) or (NS0). The relative
concentrations of the antibodies were confirmed by sandwich
ELISA, using goat anti-human IgG, Fc-specific antibodies and
HRPO-conjugated goat anti-human k light chains antibodies
(Sigma, Poole, UK).
Measurement of IgG binding to transfected cell lines
bearing human FccR
Cell lines transfected with appropriate cDNA expression vector
constructs to express single human FccR have been variously
obtained. For FccRI, the cell line was B2KA (S. Gorman and G.
Hale, unpublished) and CHO cells expressing FccRIIIb of
allotypes NA1 and NA2 [21] were provided by J. Bux. CHO
cell lines expressing FccRIIIa of allotypes 158F and 158V as GPI-
anchored receptors or the various FccRII molecules as trans-
membrane proteins with native cytoplasmic domains have been
constructed [22,23]. Continued and uniform expression of the
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appropriate FccR was confirmed in each antibody binding assay
by staining a sample of the cells for the receptor. Cells were
incubated with CD64 (clone 10.1), CD32 (AT10) or CD16
(LNK16) monoclonal antibody (AbD Serotec, Kidlington, UK)
and its binding detected with FITC-conjugated goat anti-mouse
IgG antibodies (Sigma).
Binding of monomeric Fog-1 IgG to B2KA cells expressing
FccRI was measured as previously described using Fog-1 IgG2
antibody, produced in YB2/0, as a negative control [17].
Monomeric binding of IgG to FccRIIIa was detected by the same
protocol but using biotinylated goat F(ab9)2 anti-human k
(Rockland) followed by ExtrAvidin FITC (Sigma). Complexed
Fog-1 antibody binding to FccRII and III receptors was measured
by pre-incubating the test antibodies with equimolar amounts of
goat F(ab9)2 fragments that recognise human k chain (Rockland)
[19]. Human IgA1, k purified myeloma protein (The Binding Site,
Birmingham, UK) was used as a negative control test antibody.
Complexes were detected using FITC-conjugated F(ab9)2 frag-
ments of rabbit anti-goat IgG, F(ab9)2-specific antibodies (Jackson
ImmunoResearch, Newmarket, UK) or FITC-conjugated donkey
anti-goat IgG antibodies (Serotec). The mean fluorescence of cells
from each sample was determined using a CyAn ADP flow
cytometer and Summit v4.3 software (DakoCytomation, Ely, UK)
or on a FACScan flow cytometer using LysisII software (Becton
Dickinson, Oxford, UK).
Fold-differences in IgG binding were calculated as follows:
Firstly, a curve was fitted to a subset of the mean fluorescence data
of G1 (YB2/0), the higher-binding IgG. This was a logarithmic
curve for the complexed IgG binding or a sigmoidal curve for the
monomeric IgG binding. Using the mean fluorescence values of
each of the three highest concentrations of the other IgG, the ratio
of concentrations of the two IgG giving these mean fluorescence
values was calculated. This was carried out for three or more
independent experiments so that the fold-difference in binding
could be expressed as the mean6sd of at least nine values.
Rosetting assays
O, RhD-positive RBC, which were shown to carry 9000 RhD
sites/cell by SOL-ELISA [8], were incubated with dilutions of
Fog-1 antibodies in V-bottom plates for 1 hour at room
temperature. The cells were pelleted, washed three times in
150 ml/well PBS and resuspended in 100 ml RPMI (approximately
1% suspension). CHO+FccRIIIa 158F or 158V cells were
harvested using Cell Dissociation Buffer (Invitrogen), washed,
resuspended at 46106 cells/ml and 100 ml samples added to the
sensitised RBC. The cells were pelleted together at 2006 g for
2 min and incubated on ice for 1 h. 10 ml samples were
transferred to slides with coverslips and representative images
captured at 406magnification.
Assays of functional responses to Fog-1
antibody-sensitised RBC
ADCC, macrophage adhesion and phagocytosis and monocyte
activation assays were carried out using human cells as described
previously [23]. NK cell activation was assessed using a method
adapted from [24]. Peripheral blood mononuclear cells (PBMC)
were prepared from FCGR3A- and FCGR2C-genotyped donors
by adding 6 ml samples of EDTA-anti-coagulated blood to 45 ml
samples of RBC lysis buffer (150 mM NH4Cl, 10 mM KHCO3,
1 mM EDTA) and incubating at room temperature for 15 min.
White cells were collected by centrifugation, washed in RBC lysis
buffer and resuspended in complete RPMI (RPMI containing
10% heat-inactivated FBS, 2 mM L-glutamine, 0.5 mg/ml am-
photericin B, 100 U/ml penicillin, 0.1 mg/ml streptomycin).
Using the same donor as for the rosetting assays above, RBC
were prepared by pelleting cells from 100 ml blood, washing twice
in 1 ml RPMI and resuspending in complete RPMI. Samples of
test antibody, 105 PBMC, 46105 RBC were added to round-
bottomed wells in 100 ml complete RPMI in triplicate and
incubated at 37C in a humidified atmosphere of 5% CO2 in air
for 20 h. Control wells omitted test antibody or used 10 mg/ml
IgG1 of irrelevant specificity. The surface expression of CD54 on
NK cells (identified as CD32CD56+) was determined by flow
cytometry: The cells in each well were washed three times with
FACS wash buffer (PBS containing 0.1% BSA, 0.1% NaN3) then
incubated in 100 ml FACS wash buffer containing PerCP/Cy5.5-
conjugated CD3 (clone UCHT1), PE-conjugated CD56 (clone
HCD56) and APC-conjugated CD54 (clone HA58, all from
BioLegend, London, UK) for 45 minutes on ice. The cells were
washed twice and fixed in 1% formaldehyde. Samples were
analysed using a CyAn ADP flow cytometer and Summit v4.3
software with appropriate compensation settings. Mean APC
fluorescence intensity was calculated for at least 2000
CD32CD56+ cells from each well and plotted as mean6SD of
the triplicate samples at each test antibody concentration. Samples
containing control IgG1 antibody or RhD negative RBC showed
no increase in APC fluorescence relative to samples containing no
test antibody.
FCGR3A and FCGR2C genotyping
Typing for the FccRIIIa 158F/V polymorphism was carried
out on genomic DNA that had been purified using the QIAamp
DNA Blood Mini Kit (Qiagen, Manchester, UK). A 235 bp
section of DNA, which comprised parts of the 5th exon and
following intron, was amplified using oligonucleotides (59 CAT-
ATTTACAGAATGGCAAAGG 39, 59 CAACTCAACTTCC-
CAGTGTGAT 39) that each mismatch the closely homologous
FCGR3B gene at their 39 nucleotide. The PCR products were
directly sequenced using the second primer. Lack of FCGR3B
contamination was confirmed by examining the electropherogram
at two positions within the amplified DNA where the FCGR3A
and FCGR3B sequences differ and the presence of the TTT (F)
codon, GTT (V) codon or a mixture was determined.
High homology between the ectodomains of FccRIIb and
FccRIIc means that FccRIIc typing requires amplification of
cDNA to enable use of a FccRIIb/c-specific primer at the 59 end
and a FccRIIa/c-specific primer at the 39 end. Whole blood was
diluted 10-fold with RBC lysis buffer and the white cells collected
by centrifugation. These were lysed and stored in RNASafer
(Omega bio-tek, Lutterworth,UK) before RNA was prepared
using Tripure reagent (Roche, Burgess Hill, UK). First strand
cDNA was synthesised from a FccRIIa/c-specific primer (59
AGCAAGTCTAGAGTATGACCACATGGCATAACGTTAC-
TCTTTAG 39) and was amplified by PCR using the same
oligonucleotide in conjunction with a FccRIIb/c-specific primer
(59 GACTGCTGTGCTCTGGGCGCCAGCTCGCTCCA 39).
Product was subjected to a second round of PCR using primers F
(59 AGGGAGTGATGGGAATCCTGTCATT 39) and R (59
CATAGTCATTGTTGGTTTCTTCAGG 39). The nested PCR
product was directly sequenced from primer F2 (59 CAT-
ATGCTTCTGTGGACAGCT 39). For this cDNA segment, the
FccRIIc ORF and STP alleles differ at 3 positions in addition to
the CAG (Q)/TAG (STP) codon corresponding to amino acid
residue 13 [25].
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Results
Comparison of binding of YB2/0 and NS0-generated
antibodies to human FccR
We used transfected cell lines, each expressing a single human
FccR, to pinpoint the effects on FccR binding of changing the IgG
production cell line. For FccRIIa, FccRIIIa and FccRIIIb,
functional polymorphisms are known [26] and testing was
performed for two allotypes of each receptor. The IgG were
titrated to obtain receptor-binding curves from which any
differences in strengths of binding could be calculated. Such
comparisons are traditionally made by relating the concentrations
of each antibody required to give half-maximal binding but, for
the IgG concentrations used here, either maximal binding was not
achieved by the higher-binding IgG or the lower-binding IgG did
not reach the half-maximal binding level. Therefore, comparison
was made between the binding signals detected for the highest
three concentrations of the lower-binding IgG and the binding
curve of the higher-binding IgG as described in Materials and
Methods.
Given the previous reports of FccRIIIa importance in RBC
clearance, we began by examining binding to this receptor. The
binding of pre-complexed Fog-1 G1 (YB2/0) antibody to cells
expressing FccRIIIa of allotype 158F was 45-fold higher than that
of pre-complexed G1 (NS0) (45617 fold over 5 experiments;
Figure 1A). For the higher affinity allotype of the receptor,
FccRIIIa 158V, G1 (YB2/0) complexes bound 20-fold better than
complexes of the NS0-produced antibody (2065 fold over 3
experiments; Figure 1B). This assay of complexed IgG binding to
FccRIIIa is sufficiently sensitive for binding of the Fog-1 IgG1
mutant with reduced effector function (Fog-1 G1Dnab) to be
detected at the highest IgG concentrations used. Binding of
G1Dnab (YB2/0) to the FccRIIIa 158F and 158V molecules is 51-
fold and 63-fold lower, respectively, than that of G1 (YB2/0)
(158F: 51612 fold over 3 experiments; 158V: 63618 fold over
only 2 experiments). Switching to NS0 for G1Dnab antibody
production only gives a small additional decrease in binding.
FccRIIIa is classed as a medium affinity Fc receptor and its
interactions with monomeric antibody samples can also be
measured. This was carried out to ensure that superiority of the
YB2/0-derived antibody was not an artefact of the complexed
antibody assay system. By this method, G1 (YB2/0) bound 102-
fold and 97-fold more efficiently than G1 (NSO) to the 158F and
158V allotypes of the receptor respectively (158F: 102625 fold
over 3 experiments; 158V: 97633 fold over 3 experiments;
Figure 1C and D). The higher affinity of the 158V allotype of the
receptor is clearly evident here since the binding curves for this
allotype are displaced towards lower concentrations compared to
the curves for the F allotype.
As an additional binding measurement, Fog-1 G1-sensitised
RBC were tested for their ability to rosette the receptor-bearing
cells. Figure 1, panels E - H show photographs from a
representative experiment carried out with the FccRIIIa 158V
cell line. IgG with Fog-1 variable regions are known to give 100%
saturation of RBC RhD sites (equivalent to 9000 IgG/RBC in
these experiments) at a coating concentration of approximately
20 mg/ml and 50% saturation at 0.4 mg/ml (data not shown). A
reduction in G1 (NSO) coating concentration from 100 mg/ml to
11 mg/ml reduced rosette formation even though this does not
represent a large change in terms of IgG/RBC. Tight rosettes,
similar to those seen at100 mg/ml G1 (NSO), were formed by
RBC coated with G1 (YB2/0) at 1.1 mg/ml or approximately
6000 IgG/RBC. The difference between the G1 (YB2/0) and G1
(NSO) coating concentrations that gave equivalent levels of
rosetting was greater in the case of the FccRIIIa 158F cell line
(data not shown).
We went on to compare the binding of monomeric YB2/0- and
NS0-produced immunoglobulin to the high affinity FccRI and
complexed antibody binding to the remaining human FccR,
which are of low affinity. Very similar binding of the two IgG1
antibodies was observed for FccRI, FccRIIa (of allotypes 131R
and 131H) and FccRIIb (Figure 2, panels A–D). In contrast, for
FccRIIIb of NA1 and NA2 allotypes (Figure 2E and F), there were
large differences in binding with the YB2/0-produced IgG1 being
39-fold and 38-fold better respectively (NA1: 39612 fold over 3
experiments; NA2: 38610 fold over 3 experiments). These
differences are comparable to those measured for the FccRIIIa
molecules.
Measurement of functional cellular responses to
Fog-1-sensitised RBC
Measurement of NK cell-mediated ADCC of Fog-1 IgG-
sensitised RBC showed G1 (YB2/0) to cause lysis about 100-fold
more efficiently than G1 (NS0) at sub-saturating concentrations
(Figure 3A). However, the lysis mediated by G1 (NS0) was still
higher than the background levels of lysis that were typical of
G1Dnab (YB2/0).
We also examined the interaction with NK cells by using flow
cytometry to measure the levels of the NK cell activation marker
CD54 after overnight co-culture of PBMC and RBC in the
presence of Fog-1 antibody. Results are shown for three donors of
PBMC with different FCGR3A/FCGR2C genotypes (Figure 3,
panels B–D). G1 (YB2/0) concentrations $1 ng/ml (Figure 3B),
$10 ng/ml (Figure 3C) or $100 ng/ml (Figure 3D) produced
CD54 levels that were significantly higher than in samples with no
test antibody (p,0.05, Student’s t-test). Even at 10 mg/ml, G1
(NS0) caused little increase in CD54 level with the fluorescence
signals being similar to those seen in response to G1Dnab or non-
specific IgG1 control and in samples without test antibody. Since
10 mg/ml G1 (NS0) generated a CD54 level that was similar to or
lower than 10 ng/ml G1 (YB2/0), the two IgG appear to be at
least 1000-fold different in their abilities to activate NK cells.
The activities of G1 (YB2/0) and G1 (NS0) were also compared
using macrophages and monocytes as effector cells. Both of these
cell types express FccRI in addition to lower affinity receptors.
Human macrophages were obtained from adherent mononuclear
cells that had been cultured with M-CSF and differentiated with
IFNc and LPS and were CD64+, CD32+ and CD16+ by flow
cytometry (data not shown). The proportions of macrophages
found to be interacting with Fog-1 antibody-saturated RBC
following 1 h incubations were determined. For three different
macrophage donors, there was no significant difference between
the G1 (YB2/0) and G1 (NS0) samples in terms of the numbers of
RBC interacting (p = 0.4, paired Student’s t-test) or the proportion
of these that had been phagocytosed (p = 0.3) (Figure 4A).
Presence of the G1 antibodies resulted in higher macrophage/
RBC interaction rates than G1Dnab and there were no instances
of phagocytosis with the latter antibody.
Chemiluminescence assays of monocyte activation in response
to Fog-1 antibody-sensitised RBC showed Fog-1 G1 (YB2/0) to be
approximately 3-fold more efficient at activating monocytes than
G1 (NS0) (Figure 4B). G1Dnab did not cause activation.
Discussion
Our comparison of the activities of IgG1 antibodies produced in
YB2/0 and NS0 cell lines has shown heightened performance of
the YB2/0 antibody in FccRIII binding and FccRIII-mediated
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functions. With the amino acid sequence of the two IgG1
antibodies being identical, the difference in activity must be due
to variations in glycosylation. Although we did not analyse the
glycosylation profiles of the IgG tested here, previous studies have
shown that NSO-produced antibody was underglycosylated
compared to IgG produced in YB2/0, their glycan moieties
contain more fucose and less bisecting GlcNAc residues [14] and
that lower levels of fucose lead to greater efficiency in ADCC [15].
We were able to pinpoint through which receptors the
differences in activity were generated by comparing the binding
of YB2/0- and NS0-produced Fog-1 G1 to each type of human
FccR. The assays measured monomeric IgG binding to the high
affinity FccRI and medium affinity FccRIIIa and complexed IgG
binding to FccRII and FccRIII molecules. For each of the
receptors FccRI, FccRIIa 131R and131H and FccRIIb, G1
(YB2/0) and G1 (NS0) showed very similar binding to each other.
In contrast, large inequalities in binding ability between G1 (YB2/
0) and G1 (NS0) were observed in complexed IgG binding to both
FccRIIIa and FccRIIIb and in monomeric IgG binding to
FccRIIIa. In addition, Fog-1 G1 (YB2/0)-sensitised RBC readily
formed rosettes with the FccRIIIa transfectants at lower IgG
coating concentrations than Fog-1 G1 (NS0)-sensitised RBC.
The superior FccRIIIa binding of G1 (YB2/0) over G1 (NS0)
translates into greater NK cell-mediated ADCC activity as might
be expected since it is the only Fc receptor carried by NK cells in
the majority of people. In some individuals, NK cells also express
FccRIIc, a low affinity, activating receptor with identical
extracellular domains to FccRIIb. This is due to a polymorphism,
corresponding to amino acid 13 of the mature protein, where
functional FccRIIc depends on the presence of a Q codon, rather
than stop codon [27]. In addition to the ADCC assays, we
compared the abilities of the antibodies to cause NK cell activation
when incubated with PBMC and RhD-positive RBC. Fog-1 G1
(YB2/0) was much more efficient in increasing levels of the
activation marker CD54 than the NS0 antibody. Although our
study was limited to one individual of each FCGR3A 158
Figure 1. Binding interactions of YB2/0- and NS0-produced Fog-1 G1 and G1Dnab antibodies with human FccRIIIa. A–D CHO cells
expressing FccRIIIa of allotypes 158F (A, C) and 158V (B, D) were incubated with pre-complexed (A, B) or monomeric (C, D) Fog-1 IgG and binding
detected with fluorescent reagents and flow cytometry. Graphs show mean fluorescence of $12 000 cells at each antibody concentration and are
typical of the results obtained in at least three experiments with each receptor. E–H Examples of the rosetting of FccRIIIa 158V-expressing cells by
RBC sensitised with Fog-1 G1 (YB2/0) at 10 mg/ml (E) and 1.1 mg/ml (F) or with Fog-1 G1 (NS0) at 100 mg/ml (G) and 11 mg/ml (H). Images are typical of
eight independent experiments.
doi:10.1371/journal.pone.0109463.g001
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genotype, with only the VV donor being FccRIIc-positive, we did
see a trend in the lowest G1 (YB2/0) concentration at which
significant activation was detected: VV,FV,FF. This is consis-
tent with the activation being dependent on FccRIIIa avidity for
IgG.
In contrast to the large differences in activity seen in ADCC and
NK cell activation experiments, G1 (YB2/0)- and G1 (NS0)-
coated RBC interacted with macrophages to a similar extent and
there was only a three-fold variation in ability to activate
monocytes. In these two assays, the high affinity FccRI, which
binds the two antibodies equally efficiently, is present and able to
play a dominant role in the absence of high levels of competing
non-specific IgG. This is unlikely to be the case in vivo where the
concentrations of IgG mean that FccRI molecules will be occupied
by antibody and macrophage FccRIIIa becomes more important
for RBC removal.
The difference in FccRIIIa binding of IgG1 from YB2/0 and
NS0 cell lines is similar to that between YB2/0- and CHO-derived
IgG1 with the former being approximately 100-fold better at
binding to soluble FccRIIIa 158 F or V by ELISA [28]. A variant
CHO line, Lec13, produces IgG molecules with 10% fucosylation
and dimers of these IgG show up to 50-fold improved binding over
normal CHO-produced IgG to FccRIIIa a-chain in ELISAs [29].
Lower fucose gave less improvement when measuring the binding
of trimers or mutated IgG with an intrinsically higher affinity for
FccRIIIa. This concurs with the results of our three measurements
of FccRIIIa binding where the greatest difference was observed
when monomeric IgG was tested. These groups [28,29] showed
essentially identical binding of their glycosylation variants to
FccRI and FccRIIa, allotype 131H although the low fucose
antibodies gave slightly higher signals with FccRIIa, allotype 131R
and FccRIIb. The difference in ADCC efficacy between G1
(YB2/0) and G1 (NS0) is also similar to that observed between
YB2/0- and CHO-derived IgG1 in several studies. In ADCC
assays using 20 different donors of PBMC, a YB2/0-produced
version of the CD20 therapeutic antibody, rituximab, was 10–100
fold better than the original CHO-produced antibody [28]. YB2/
0–produced IgG gave equivalent levels of ADCC to CHO-made
antibody at lower antigen densities [30], at lower antibody
concentrations or with lower numbers of effector cells [31].
The effect of switching from CHO- to YB2/0-produced IgG1
on the interaction with FccRIIIa has also been analysed by surface
plasmon resonance and isothermal titration calorimetry [32]. The
enhancement of affinity arises mainly from an increased associ-
ation rate that is a consequence of greater favourable enthalpy and
implies additional non-covalent interactions. In line with the
approximate 100-fold difference we saw between monomeric
YB2/0- and NS0-produced IgG1binding to cell-surface FccRIIIa,
low-fucose IgG1was shown to have a 50-fold greater affinity than
high-fucose IgG1 for soluble FccRIIIa 158V by surface plasmon
resonance [33]. Mutation of the receptor residue N162 reduced
the affinity of low-fucose IgG1 by 13-fold whilst increasing that of
high-fucose IgG1 by 3-fold. The authors infer that a high affinity
interaction requires glycosylation at N162 of the receptor but that
this carbohydrate can only have productive contacts with
nonfucosylated IgG. The fucose residue, which protrudes from
the carbohydrate core, may prevent close approach of the
molecules. Although the crystal structure of an IgG1-Fc fragment
in complex with FccRIIIb was solved using aglycosyl receptor
[34], it does indicate that a carbohydrate moiety attached to
receptor residue N162 would be orientated towards the carbohy-
drate of the Fc. Only FccRIIIa and FccRIIIb of human FccR
Figure 2. Binding of YB2/0- and NS0-produced Fog-1 G1 antibodies to human FccR. A Binding of monomeric IgG was measured for FccRI
using the B2KA cell line and flow cytometry. Fog-1 IgG2 antibody, produced in the YB2/0 cell line, was used as the non-binding control antibody for
this receptor. B–F Binding of pre-complexed IgG was measured using CHO cell lines expressing the low affinity receptors which were FccRIIa,
allotypes 131R (B) and 131H (C), FccRIIb (D) and FccRIIIb, allotypes NA1 (E) and NA2 (F). The level of background binding is given by the negative
control antibody, IgA,k. Graphs show mean fluorescence of $12 000 cells at each antibody concentration and are typical of the results obtained in at
least three experiments with each receptor.
doi:10.1371/journal.pone.0109463.g002
A Functional Comparison of Human IgG1 Anti-RhD from Two Cell Lines
PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e109463
have a glycosylation site at position162, which accounts for the
selectivity of the fucose effect.
Features of Fog-1 G1 (YB2/0)-mediated RBC clearance in vivo,
namely the accumulation of RBC in the liver and the presence of
radioactivity in the plasma [8], have raised concern about the use
of YB2/0-produced IgG in the prevention of alloimmunisation
[5]. The hepatic uptake could be indicative of YB2/0-derived
antibodies having pro-inflammatory interactions via their carbo-
hydrate residues with molecules of the innate immune system.
Accumulation in the liver, in addition to the spleen, occurred in
two subjects with.11000 IgG1 molecules/RBC (or more than
40 mg IgG1/ml packed cells) but not in a subject with
6800 molecules/cell. This accumulation must be FccR-dependent
since it did not occur in two subjects where RBC were coated with
Fog-1 G1Dnab at.15000 molecules/cell. Few RBC clearance
studies have included imaging but an investigation reported
hepatic uptake at high coating levels when RBC were sensitised
with different amounts of polyclonal anti-Rh antibody from
human serum [35]. Thus accumulation in the liver may be a
consequence of FccR binding of IgG that is presented at a high
density on the RBC surface rather than interactions specifically
with the glycan structure of the YB2/0-produced IgG. Most RBC
survival studies use low coating levels as they are designed to
discover if relatively low, prophylactic doses of the anti-RhD IgG
would give sufficient RBC clearance. This might also explain the
unusualness of detecting radioactivity in the plasma, which has
been suggested to imply that some RBC were destroyed by a
potentially pro-inflammatory extracellular cytotoxic mechanism
rather than by phagocytosis [5]. The fate of radioisotopes
following phagocytosis is unknown and cannot be assumed to be
the same as for other products of cell destruction such as
haemoglobin. The high rates of RBC destruction in our study may
Figure 3. Functional responses of NK cells to RBC sensitised with Fog-1 antibodies. A The specific lysis of sensitised RBC by NK-cell
mediated ADCC is presented as mean6SD of triplicate samples. This experiment used effector cells pooled from 6 donors but similar results were
obtained in four experiments with individual donors of PBMCs. B–D The activation of NK cells in response to sensitised RBC as visualised by the level
of CD54 on the surface of CD32, CD56+ lymphocytes. Each graph shows the mean6SD of triplicate samples for each data point. Donors of PBMC
were of the following genotypes: FccRIIIa 158V/V, FccRIIc 13Q/13Q (B), FccRIIIa 158F/V, FccRIIc 13STP/13STP (C) and FccRIIIa 158F/F, FccRIIc 13STP/
13STP (D). CD54 signals for samples with no test antibody were 14.260.1 (B), 17.062.5 (C) and 13.061.1 (D). CD54 signals for samples incubated with
irrelevant IgG1 were 13.360.4 (B), 18.764.1 (C) and 12.160.9 (D).
doi:10.1371/journal.pone.0109463.g003
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account for the levels of radiolabel in the plasma. These peaked at
4–6% injected dose 100 min post-injection, by which time more
than 95% of the injected doses had disappeared from the cell
fractions [8]. Mollison et al. [35] saw comparable levels of plasma
radioactivity where there were rapid rates of destruction but most
studies have not reported plasma radioactivities. In addition to
Fog-1 IgG1, two other YB2/0-produced anti-RhD antibodies
have been tested in humans. R297 was found to be at least as
effective as commercially-available polyclonal anti-RhD in clear-
ing RBC [36]. Its derivative, R593 (roledumab), is undergoing
clinical trials [37] and has been shown to be well tolerated and
have a similar pharmacokinetic profile to human polyclonal anti-
RhD [38].
Superior ADCC activity, as afforded by YB2/0 production, can
be achieved by alternative methods of controlling the level of
antibody fucosylation (reviewed [39]). Ideally, all carbohydrate
moieties within the therapeutic antibody sample should be without
fucose since fucosylated molecules in mixtures can complete for
antigenic sites on target cells and batch-to-batch variation in
carbohydrate composition is a regulatory issue. A FUT82/2 CHO
line that produces completely non-fucosylated antibodies but
retains the growth characteristics of parent is attractive to the
biopharmaceutical industry [40]. In ADCC, FUT82/2 CHO-
produced chimeric anti-CD20 IgG1 was 100-fold more efficient
than original rituximab and 2–3 fold better than YB2/0-produced
antibody and enhancement was also seen for the other IgG
subclasses [41]. As well as being an effective method of improving
activity, removal of fucose should not result in immunogenicity
since 10–20% of normal human IgG lacks fucose [42]. Clinical
trials have shown that non-fucosylated antibodies are tolerated and
can give clinical effects at low doses [43,44].
This work has capitalised on a unique opportunity to compare
the effects of alternative glycosylation profiles on the in vivo and in
vitro properties of IgG molecules with the same amino acid
sequence. Our comparison of YB2/0- and NS0-produced IgG1
antibodies has revealed that differences in Fc receptor binding are
confined to FccRIII and amount to 100-fold higher binding of
YB2/0-produced IgG1 in the case of monomeric IgG binding to
FccRIIIa. The previously-reported underglycosylation of IgG
from NS0 cells [14] would be expected to reduce binding to all
FccR but our results showed very similar binding to receptors of
the FccRI and FccRII classes. The greater ability of Fog-1 IgG1
from YB2/0 cells, compared to the original Fog-1 from human-
mouse heterohybridoma cells, to clear RBC in vivo therefore
results from its improved FccRIII binding. These pieces of
evidence confirm the importance of FccRIII in RBC clearance.
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